Side by side
How the two compare across structure, mechanism studied, evidence and regulatory status, based on published research.
| Property | Semaglutide | Tirzepatide |
|---|---|---|
| Class | GLP-1 receptor agonist | Dual GIP / GLP-1 receptor agonist |
| Research category | type 2 diabetes and obesity | type 2 diabetes and obesity |
| Evidence level | High | High |
| Overall status | Approved (Rx) — type 2 diabetes, weight management and CV risk reduction | Approved (Rx) — type 2 diabetes and chronic weight management |
| FDA | Approved (Rx) | Approved (Rx) |
| EMA | Approved (Rx) | Approved (Rx) |
| WADA | Not listed — check current list | Not listed — check current list |
| Mechanism studied | Semaglutide → GLP-1 receptor → Insulin, glucagon & satiety → Weight & glucose endpoints | Tirzepatide → GIPR + GLP-1R → Insulin & satiety signalling → Glucose & body-weight endpoints |
| Molecular weight | 4,113.6 g/mol | 4,813.5 g/mol |
| Sizes in stock | Not currently listed | , , , , , |
Where the research overlaps
Both compounds are studied within Metabolic & GLP-1 research. Semaglutide is classed as glp-1 receptor agonist, while Tirzepatide is dual gip / glp-1 receptor agonist. Evidence is rated high for Semaglutide and high for Tirzepatide.
For a full write-up, read Peptide Half-Life Engineering: Lipidation, PEG and DAC.
FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.